Ahola, Aila J. http://orcid.org/0000-0001-5200-4597
Tikkanen-Dolenc, Heidi
Forsblom, Carol
Harjutsalo, Valma
Groop, Per-Henrik
,
Funding for this research was provided by:
Academy of Finland (316664)
Novo Nordisk Fonden (OC0013659)
Signe ja Ane Gyllenbergin Säätiö
Folkhälsan Research Foundation
Helsinki University Hospital Research Funds (TYH2018207)
Wilhelm och Else Stockmanns Stiftelse
Medicinska Understödsföreningen Liv och Hälsa
Päivikki ja Sakari Sohlbergin Säätiö
University of Helsinki including Helsinki University Central Hospital
Article History
Received: 12 February 2021
Accepted: 5 April 2021
First Online: 19 May 2021
Declarations
:
: Professor Per-Henrik Groop has received investigator-initiated grants from Eli Lilly and Roche and is an advisory board member for AbbVie, Astellas, Astra Zeneca, Bayer, Boehringer-Ingelheim, Eli Lilly, Janssen, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, and Sanofi. He has received lecture honoraria from Astellas, Astra Zeneca, Boehringer-Ingelheim, Eli Lilly, Elo Water, Genzyme, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, PeerVoice, Sanofi and Sciarc. All other authors declare no conflicts of interest.
: The Ethics Committee of Helsinki and Uusimaa Hospital District approved the study protocol. The study was carried out in accordance with the Declaration of Helsinki and its later amendments.
: Written informed consent was obtained from all individuals prior to study participation.